Protalix Biotherapeutics Inc PLX
$2.38
Last Updated: Aug 21, 12:00 AM·XASE
Pricing for US stocks is delayed by 24 hours
PLX Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Protalix Biotherapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Protalix Biotherapeutics Inc. Stock Analysis PLX
United States Health Care Micro Cap Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. The company is headquartered in Hackensack, New Jersey and currently employs 226 full-time employees. The company went IPO on 2010-09-06. The firm is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Protalix Biotherapeutics Inc (PLX) Chart
Financial Metrics & Statements of Protalix Biotherapeutics Inc (PLX)
FAQ's for Protalix Biotherapeutics Inc (PLX)
- As of August 2026, Protalix Biotherapeutics Inc PLX is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Protalix Biotherapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Protalix Biotherapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Protalix Biotherapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Protalix Biotherapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Protalix Biotherapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Protalix Biotherapeutics Inc (PLX)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
